Cambridge Healthtech Institute第5屆

Adoptive T Cell Therapy 1: Discovery

( 過繼T細胞免疫療法1:創藥 )

2018年8月28日~29日


本單元以過繼T細胞免疫療法的創藥為主題,內容將聚焦於選定、改變、強化、向病患提供具有發展潛力的T細胞療法藥物之必要步驟。

Coverage will include, but is not limited to:

Principles of engineered receptor design

  • Chimeric antigen receptors (CAR)
  • T cell receptors (TCR)
  • Tumor infiltrating lymphocytes (TIL)

Other cellular subtypes

  • Natural killer cells (NK)
  • Cytotoxid T lymphocytes (CTLs)
  • Tregs

Advances in the selection of optimal T cells

New techniques in T cell engineering

  • Gating strategies
  • Antigen presentation
  • New approaches to activation and engagement

Biological switches

  • Kill switches
  • Activation switches

Toxicity

  • Understanding mechanisms
  • Evolution of synthetic cells and their long-term efficacy

Genome editing

  • CRISPR/Cas9
  • Zinc finger nucleases
  • TAL

Enabling technologies and platforms

* 活動內容有可能不事先告知作更動及調整。

Choose your language
Chinese
Japanese
Korean
English





免費電子郵件通知服務